Switch to:
Also traded in: Germany
» Details

Insider Trades

Latest Guru Trades with GALT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:IMMY, OTCPK:ACNNF, NAS:JNP, NAS:EVOK, OTCPK:MRPHF, OTCPK:NRIFF, OTCPK:ITHUF, OTCPK:KAYS, OTCPK:MGWFF, NAS:PSDV, OTCPK:SPLIF, NAS:FCSC, NAS:OREX, NAS:MEIP, NAS:STDY, NAS:EPIX, OTCPK:AOLS, NAS:ARDM, NAS:BNTC, OTCPK:CVSI » details
Traded in other countries:PHPN.Germany,
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galectin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.

Ratios

vs
industry
vs
history
P/B 11.76
GALT's P/B is ranked lower than
91% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. GALT: 11.76 )
Ranked among companies with meaningful P/B only.
GALT' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 457.5
Current: 11.76
0
457.5
Current Ratio 3.94
GALT's Current Ratio is ranked higher than
68% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. GALT: 3.94 )
Ranked among companies with meaningful Current Ratio only.
GALT' s Current Ratio Range Over the Past 10 Years
Min: 0.2  Med: 4.12 Max: 23.21
Current: 3.94
0.2
23.21
Quick Ratio 3.94
GALT's Quick Ratio is ranked higher than
75% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. GALT: 3.94 )
Ranked among companies with meaningful Quick Ratio only.
GALT' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 4.12 Max: 23.21
Current: 3.94
0.2
23.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.50
GALT's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. GALT: -21.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GALT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -18.65 Max: -10.6
Current: -21.5
-26.1
-10.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.20
GALT's Price/Net Cash is ranked higher than
78% of the 250 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.84 vs. GALT: 4.20 )
Ranked among companies with meaningful Price/Net Cash only.
GALT' s Price/Net Cash Range Over the Past 10 Years
Min: 2.69  Med: 12.28 Max: 210
Current: 4.2
2.69
210
Price/Net Current Asset Value 11.31
GALT's Price/Net Current Asset Value is ranked lower than
65% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. GALT: 11.31 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GALT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.69  Med: 12.4 Max: 732
Current: 11.31
2.69
732
Price/Tangible Book 11.31
GALT's Price/Tangible Book is ranked lower than
87% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. GALT: 11.31 )
Ranked among companies with meaningful Price/Tangible Book only.
GALT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.71  Med: 12.3 Max: 430
Current: 11.31
2.71
430
Earnings Yield (Greenblatt) (%) -56.80
GALT's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. GALT: -56.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GALT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -25770.33  Med: 0 Max: 4520.18
Current: -56.8
-25770.33
4520.18

More Statistics

EPS (TTM) $ -0.82
Beta2.94
Short Percentage of Float4.49%
52-Week Range $0.49 - 3.05
Shares Outstanding (Mil)32.21

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.54 -0.48 -0.74 -1.04
EPS w/o NRI ($) -0.54 -0.48 -0.74 -1.04
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for GALT

Headlines

Articles On GuruFocus.com

More From Other Websites
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Feb 17 2017
Galectin Therapeutics to Present at BIO CEO & Investor Conference Feb 08 2017
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 07 2017
Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models... Feb 07 2017
Galectin Therapeutics Presentation Now Available for On-Demand Viewing Feb 06 2017
Galectin Therapeutics Presentation Now Available for On-Demand Viewing Feb 06 2017
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 02 2017
Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial Feb 01 2017
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 01 2017
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present... Jan 30 2017
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present... Jan 30 2017
Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2 Jan 30 2017
Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2 Jan 30 2017
Galectin Therapeutics Announces $4 Million in New Equity Financings Dec 29 2016
Galectin Therapeutics Announces $4 Million in New Equity Financings Dec 29 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 29 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 20 2016
Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders Dec 08 2016
GALECTIN THERAPEUTICS INC Financials Nov 15 2016
Galectin Buoyed By Plaque Psoriasis Study (GALT) Nov 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK